142 related articles for article (PubMed ID: 10486880)
1. [Efficiency, safety and tolerability of recombinant human interleukin-3 (rhIL-3) as supportive therapy accompanying dose-intensive carboplatin containing chemotherapy in ovarian cancer with special regard to thrombocytopenia].
Meden H; Fock M; Krauss T; Kuhn W
Zentralbl Gynakol; 1999; 121(8):375-83. PubMed ID: 10486880
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of recombinant interleukin 3 before and after carboplatin/etoposide chemotherapy in patients with solid tumors: a southwest oncology group study.
Rinehart J; Margolin KA; Triozzi P; Hersh E; Campion M; Resta D; Levitt D
Clin Cancer Res; 1995 Oct; 1(10):1139-44. PubMed ID: 9815905
[TBL] [Abstract][Full Text] [Related]
3. Randomized trial of recombinant human interleukin-3 versus placebo in prevention of bone marrow depression during first-line chemotherapy for ovarian carcinoma.
Hofstra LS; Kristensen GB; Willemse PH; Vindevoghel A; Meden H; Lahousen M; Oberling F; Sorbe B; Crump M; Sklenar I; Sluiter WJ; Kiese B; Trope CG; de Vries EG
J Clin Oncol; 1998 Oct; 16(10):3335-44. PubMed ID: 9779710
[TBL] [Abstract][Full Text] [Related]
4. Recombinant human interleukin-3 to dose-intensify carboplatin and cyclophosphamide chemotherapy in epithelial ovarian cancer: a phase I trial.
Veldhuis GJ; Willemse PH; van Gameren MM; Aalders JG; Mulder NH; Mull B; Biesma B; de Vries EG
J Clin Oncol; 1995 Mar; 13(3):733-40. PubMed ID: 7884433
[TBL] [Abstract][Full Text] [Related]
5. [Effectiveness and safety of recombinant human interleukin-11 in the treatment of chemotherapy-induced thrombocytopenia].
Lei W; Liang J; Chen WG; Ma XZ; Xu M; Du LL
Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):542-4. PubMed ID: 17147124
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of recombinant human interleukin 3 administered subcutaneously and by continuous intravenous infusion in patients after chemotherapy for ovarian cancer.
Biesma B; Pokorny R; Kovarik JM; Duffy FA; Willemse PH; Mulder NH; de Vries EG
Cancer Res; 1993 Dec; 53(24):5915-9. PubMed ID: 8261403
[TBL] [Abstract][Full Text] [Related]
7. Apparent stimulation of thrombopoesis with interleukin-3 (IL-3) in chemotherapy induced myelosuppression.
Schweiger C; Färber L; Füchsel G; Heinrich D; Meinerz W
Biofactors; 1995-1996; 5(2):73-4. PubMed ID: 8722119
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II dose escalation study of recombinant human interleukin-11 following ifosfamide, carboplatin and etoposide in children, adolescents and young adults with solid tumours or lymphoma: a clinical, haematological and biological study.
Cairo MS; Davenport V; Bessmertny O; Goldman SC; Berg SL; Kreissman SG; Laver J; Shen V; Secola R; van de Ven C; Reaman GH
Br J Haematol; 2005 Jan; 128(1):49-58. PubMed ID: 15606549
[TBL] [Abstract][Full Text] [Related]
9. Further studies to ameliorate toxicity of carboplatin.
ten Bokkel Huinink WW; Dercksen MW; van Tinteren H
Semin Oncol; 1994 Apr; 21(2 Suppl 2):27-33; quiz 34, 58. PubMed ID: 8202718
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer.
Tung N; Berkowitz R; Matulonis U; Quartulli M; Seiden M; Kim Y; Niloff J; Cannistra SA
Gynecol Oncol; 2000 May; 77(2):271-7. PubMed ID: 10785477
[TBL] [Abstract][Full Text] [Related]
11. High-dose platinum versus standard dose in advanced ovarian carcinoma: a randomized trial from the Gynecologic Cooperative Group of the French Comprehensive Cancer Centers (FNCLCC).
Joly F; Héron JF; Kerbrat P; Chauvergne J; Rios M; Mayer F; Chinet-Charrot P; Goupil A; Lebrun-Jezekova D; Vennin D; Lhommé C; Macé-Lesec'h J; Crouet H
Gynecol Oncol; 2000 Sep; 78(3 Pt 1):361-8. PubMed ID: 10985895
[TBL] [Abstract][Full Text] [Related]
12. [Effectiveness and safety of rhIL-11 in the treatment of chemotherapy-induced thrombocytopenia].
Li L; Xu CG; Wang XW; Guo QS; Sun YH; Sun LM
Zhonghua Zhong Liu Za Zhi; 2005 Jun; 27(6):377-9. PubMed ID: 16117904
[TBL] [Abstract][Full Text] [Related]
13. First-line chemotherapy with weekly paclitaxel and carboplatin for advanced ovarian cancer: a phase I study.
Sehouli J; Stengel D; Elling D; Ortmann O; Blohmer J; Riess H; Lichtenegger W;
Gynecol Oncol; 2002 May; 85(2):321-6. PubMed ID: 11972395
[TBL] [Abstract][Full Text] [Related]
14. The clinical development of recombinant human interleukin 11 (NEUMEGA rhIL-11 growth factor).
Kaye JA
Stem Cells; 1996; 14 Suppl 1():256-60. PubMed ID: 11012229
[TBL] [Abstract][Full Text] [Related]
15. Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer.
Bolis G; Scarfone G; Giardina G; Villa A; Mangili G; Melpignano M; Presti M; Tateo S; Franchi M; Parazzini F;
Gynecol Oncol; 2001 Apr; 81(1):3-9. PubMed ID: 11277642
[TBL] [Abstract][Full Text] [Related]
16. [Phase II clinical trial on China manufactured recombinant human interleukin-11 derivative in the prevention and treatment of chemotherapy-induced thrombocytopenia].
Wang XY; Feng FY; Song ST; Wang HQ; Zhang MH; Liu J; Liu XY; Xu LG; Zhang Y
Zhonghua Zhong Liu Za Zhi; 2005 Jun; 27(6):373-6. PubMed ID: 16117903
[TBL] [Abstract][Full Text] [Related]
17. A comparative study on hematological effects of carboplatin plus cyclophosphamide and carboplatin plus paclitaxel chemotherapy for the first line treatment of epithelial ovarian cancer.
Vapattanawong P
J Med Assoc Thai; 2006 Sep; 89(9):1357-61. PubMed ID: 17100369
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of recombinant human interleukin 3 administration following carboplatin and etoposide chemotherapy in small-cell lung cancer patients. SDZ ILE 964 (IL-3) Study.
Kudoh S; Sawa T; Kurihara N; Furuse K; Kurita Y; Fukuoka M; Takada M; Takaku F; Ogawa M; Ariyoshi Y
Cancer Chemother Pharmacol; 1996; 38 Suppl():S89-95. PubMed ID: 8765425
[TBL] [Abstract][Full Text] [Related]
19. Combined weekly carboplatin and paclitaxel as primary treatment of advanced epithelial ovarian carcinoma.
Safra T; Menczer J; Bernstein RM; Shpigel S; Matcejevsky D; Inbar MJ; Golan A; Grisaru D; Levy T
Gynecol Oncol; 2009 Aug; 114(2):215-8. PubMed ID: 19446318
[TBL] [Abstract][Full Text] [Related]
20. Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group.
Bamias A; Papadimitriou C; Efstathiou E; Rodolakis A; Vlahos G; Voulgaris Z; Bozas G; Fountzilas G; Aravantinos G; Razis E; Gika D; Dimopoulos MA
BMC Cancer; 2006 Sep; 6():228. PubMed ID: 16999858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
